改良第四代免疫分析法HIV亲和力指数鉴别近期感染的表现
研究评估亲和力指数(AI)鉴别近期与既往HIV-1感染的诊断性能,采用Architect HIV Ag/Ab Combo第四代试验检测647份血清样本。近期感染组平均AI显著低于既往感染组(0.66+0.28 vs 1.00±0.12,p<0.000),切点≤0.70时误分类率(FRR)为0%,AI满足WHO对HIV发病率检测的要求。
要点
- AI切点≤0.70时误分类率为0%,可准确区分近期与既往HIV感染。
- 近期感染组平均AI显著低于既往感染组(0.66+0.28 vs 1.00±0.12)。
- HIV亚型对AI误分类无影响,精英控制者及低VL/CD4样本FRR极低。
核心结论
- AI是鉴别近期与既往HIV感染的准确血清学标志物,满足WHO对HIV发病率检测的要求。
研究设计与样本
- 收集HIV-1阳性个体血清样本,A组为已知感染日期者,B组为感染超过1年者。
- 样本分别用PBS和1 M胍稀释后以Architect HIV Ag/Ab Combo第四代试验检测。
- 共647份样本:A组455份(近期感染51.6%,既往感染48.4%),B组192份。
- 采用ROC曲线分析诊断准确性,并计算误分类为近期感染的 proportion(FRR)。
主要发现
- 抗逆转录病毒治疗前样本中,近期感染组平均AI显著低于既往感染组(0.66+0.28 vs 1.00±0.12;p<0.000)。
- 切点≤0.70时FRR为0%。
- 精英控制者及低VL或低CD4样本中FRR极低。
- HIV亚型对AI误分类无影响。
- A组所有个体在血清阳转后24个月内达到AI阈值0.80。
关键数值与推荐
- AI切点≤0.70时FRR为0%。
- 近期感染组平均AI为0.66+0.28,既往感染组为1.00±0.12(p<0.000)。
- A组所有个体在血清阳转后24个月内AI达到0.80。
临床怎么用
- 可将AI作为血清学标志物用于鉴别近期与既往HIV感染,辅助发病率评估。
- 采用切点≤0.70时误分类率低,但需注意精英控制者及低VL/CD4样本中FRR极低的情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detecting recent HIV infections is important to evaluate incidence and monitor epidemic trends. We aimed to evaluate the diagnostic performance and accuracy of the avidity index (AI) for discriminating for recent HIV infections. METHODS: We collected serum samples from HIV-1 positive individuals: A) with known date of infection (midpoint in time between last HIV-negative and first HIV-positive test); B) infected for >1 year. Samples were divided into two aliquots: one diluted with phosphate buffered saline (PBS) and the other with 1 M guanidine. Both aliquots were assayed by the Architect HIV Ag/Ab Combo 4th generation assay (Abbott). We compared AI found in recent (RI=<6 months from seroconversion) and established (EI) infections. The diagnostic accuracy was evaluated by receiver operating characteristic (ROC) curve analysis. The proportion of samples misclassified as recent (FRR) was calculated. RESULTS: In total, 647 samples were collected: 455 in group A (51.6% RI and 48.4% EI) and 192 in group B. Among these, sixteen samples were from elite controllers, 294 from treated patients, 328 from patients infected with non-B subtypes. Samples before antiretroviral initiation showed a mean AI significantly lower among RI compared to EI (0.66+0.28 vs. 1.00±0.12; p<0.000). The FRR was 0% using a cut-off of ≤0.70. An extremely low FRR was observed among elite controllers, samples with low VL or CD4. HIV subtype had no impact on AI misclassifications. All individuals in group A reached the AI threshold of 0.80 within 24 months after seroconversion. CONCLUSIONS: The AI is an accurate serological marker for discriminating recent from established HIV infections and meets WHO requirements for HIV incidence assays.
引用
- Suligoi B, Regine V, Raimondo M, et al. HIV avidity index performance using a modified fourth-generation immunoassay to detect recent HIV infections. Clin Chem Lab Med. 2017. PMID: 28672745. doi:10.1515/cclm-2016-1192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。